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Toxoplasma gondii is an intracellular apicomplexan parasite, which can cause a serious infectious 
disease in pregnant women and immunocompromised individuals. Therefore, the development of a 
polyvalent vaccine consisting of all stages of the parasite life cycle using the epitopes from 
tachyzoites, bradyzoites, and sporozoites is likely to be required for complete protective immunity. 
In this study, we designed protein vaccine candidate based on the prediction of specific epitopes 
(i.e., B cell and T cell) from three Toxoplasma gondii antigens. The MRS protein (MIC3: 30–180, 
ROP8: 85–185, and SAG1: 85–235) was expressed in Escherichia coli, and purification was 
performed using a HisTrap HP column and then we evaluated immunogenicity and protective 
property in BALB/c mice. Seventy-two mice were randomly divided into six groups, including 
three vaccinations (i.e., MRS, MRS-Freund, and MRS-Calcium Phosphate Nanoparticles (MRS-
CaPNs)) and three control (i.e., Phosphate-buffered saline, Freund, and CaPNs) groups. All groups 
were immunized three times via subcutaneous injection within three-week intervals. In the 
vaccination groups, the BALB/c mice were injected with 20 μg of MRS protein for the first time 
and 10 μg of MRS for the next two times. Antibodies, cytokines, and splenocytes proliferation in 
the immunized mice were assayed using the enzyme-linked immunosorbent assay. Protective 
efficacy was analyzed by challenging the immunized mice with T. gondii of RH strain. Antibody, 
cytokine, and lymphocyte proliferation assays showed that the mice immunized with MRS induced 
stronger humoral and T helper type 1 cell-mediated immune responses, compared to the control 
mice. However, co-immunization with adjuvants (i.e., Freund and CaNPs) resulted in impaired 
immune responses. Effective protection against the parasite achieved an increase in survival time in 
the immunized mice, especially in the MRS-CaNPs group. The obtained results of the present study 
demonstrated that multi-epitope protein vaccination, MRS, is a potential strategy against 
toxoplasmosis infection. In addition, the vaccine co-delivered with CaPNs could provide an 
important key for vaccine candidate to control T. gondii infection. 
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